CA-QAD-INC
14.5.2024 09:01:37 CEST | Business Wire | Press release
QAD Inc., a leading provider of next-generation manufacturing and supply chain solutions in the cloud, has opened registration for its new EMEA customer conference, QAD Transform Europe, a complimentary two-day event happening 24-25 September in Brussels, Belgium.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240514413631/en/
Customers, sponsors and other members of the QAD community will join manufacturing and supply chain leaders from across Europe for two days of networking, education and technology innovation. Attendees will hear from industry experts and peers about the state of manufacturing and supply chains, what the future may bring and how to stay adaptive.
“QAD Transform Europe is our fresh take on regional events designed for and tailored to the customer,” said QAD Chief Product and Marketing Officer Carter Lloyds. “We recognize that manufacturing and supply chain leaders continue to face uncertainty and change in their business. The only way to survive and thrive is to transform. We look forward to sharing our roadmap for transformation at the event.”
The agenda for QAD Transform Europe will address the fundamental reasons businesses need to transform to survive, and help map the journey to get there. QAD leaders will outline the company’s plans for how to navigate today and tomorrow and QAD customers will share their success stories.
Agenda Highlights:
- Introducing the Industrial Transformation Platform — QAD’s roadmap to help companies transform into an Adaptive Enterprise by QAD CEO Anton Chilton
- Panel discussion with industry leaders on the transformation imperative
- Effective change management across your organization
- Uncovering root causes — not symptoms — of supply chain disruption
- Keynote address on QAD’s technology strategy and the benefits of the Cloud with QAD CTO Tony Winter
- Keynote address on Artificial Intelligence with Jeroen Baert, Computer Scientist, Comedian, Geek
- Leveraging pragmatic AI in supply chains
- Aligning ESG and sustainability with commercial objectives
- QAD new flagship ERP release — ERP O³
- Product updates on QAD Redzone Connected Workforce, QAD GTTE, QAD SRM, QAD DSCP and QAD Process Intelligence
- The new QAD roadmap for the food and beverage industry
- Breakout sessions and QAD Sponsor Expo
On Day 1, QAD executives and guest speakers will share an update on QAD today and the Industrial Transformation Platform, a panel discussion with industry experts on the need for transformation, the QAD roadmap and customer success stories. A networking reception and dinner with fellow manufacturing and supply chain leaders will follow.
On Day 2, guest keynotes will present on Effective Change Management, followed by a presentation on the state of Artificial Intelligence. More great breakout sessions and a networking lunch with QAD will follow as well as a Sponsor Expo to see QAD solutions in action.
The full agenda can be accessed here. For the latest updates on QAD Transform Europe, follow us on social media and engage using #QADTransform.
Event Details
What: QAD Transform Europe Customer Conference
When: 24-25 September, 2024
Where: Cardo Brussels Hotel | Brussels, Belgium
Registration: To register to attend QAD Transform Europe, click here.
About QAD – Enabling Adaptive Enterprises
QAD Inc. is a leading provider of next-generation manufacturing and supply chain solutions in the cloud. To succeed in a turbulent world, facing disruptions in supply and fluctuations in demand, manufacturers and supply chains must rapidly respond to change and seamlessly optimize agility, efficiency, and resilience for effective customer service. QAD delivers Adaptive Applications to enable these Adaptive Enterprises.
Founded in Santa Barbara, California, QAD has customers in 84 countries around the world. Thousands of companies have deployed QAD enterprise solutions including enterprise resource planning (ERP), digital commerce (DC), supplier relationship management (SRM), digital supply chain planning (DSCP), global trade and transportation execution (GTTE), enterprise quality management system (EQMS), connected workforce and process intelligence. To learn more, visit www.qad.com or call +1 805-566-6100. Find us on LinkedIn, X, Facebook and Instagram.
“QAD” is a registered trademark of QAD. All other products or company names herein may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514413631/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom